SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001219
Filing Date
2024-08-08
Accepted
2024-08-08 16:05:56
Documents
63
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cldx-20240630x10q.htm   iXBRL 10-Q 1295497
2 EX-31.1 cldx-20240630xex31d1.htm EX-31.1 11654
3 EX-31.2 cldx-20240630xex31d2.htm EX-31.2 12316
4 EX-32.1 cldx-20240630xex32d1.htm EX-32.1 7326
  Complete submission text file 0001410578-24-001219.txt   5828844

Data Files

Seq Description Document Type Size
5 EX-101.SCH cldx-20240630.xsd EX-101.SCH 32611
6 EX-101.CAL cldx-20240630_cal.xml EX-101.CAL 40291
7 EX-101.DEF cldx-20240630_def.xml EX-101.DEF 136943
8 EX-101.LAB cldx-20240630_lab.xml EX-101.LAB 333929
9 EX-101.PRE cldx-20240630_pre.xml EX-101.PRE 236148
66 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20240630x10q_htm.xml XML 1155004
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 241188191
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)